<p>Oppenheimer 在週一向投資者發佈的報告中開始覆蓋 Tarsus Pharmaceuticals (NASDAQ:TARS - 獲取免費報告) 的股票。該券商對該股票設定了 “跑贏大盤” 的評級，並給出了 75.00 美元的目標價。Oppenheimer 的目標價表明該公司股價有潛在的 76.10% 上漲空間。</p>
<p>獲取 <strong>Tarsus Pharmaceuticals</strong> 的提醒：</p>
<p>其他股票研究分析師最近也對該股票發佈了報告。巴克萊將 Tarsus Pharmaceuticals 的股票目標價從 62.00 美元下調至 60.00 美元，並在 2 月 26 日的研究報告中對該股票設定了 “增持” 評級。高盛將 Tarsus Pharmaceuticals 的股票目標價從 46.00 美元上調至 51.00 美元，並在 5 月 5 日的研究報告中給予該股票 “中性” 評級。華爾街 Zen 在 5 月 22 日的研究報告中將 Tarsus Pharmaceuticals 的股票評級從 “買入” 下調至 “持有”。古根海姆在 5 月 2 日的研究報告中將 Tarsus Pharmaceuticals 的股票目標價從 78.00 美元上調至 84.00 美元，並給予該公司 “買入” 評級。最後，HC Wainwright 在 5 月 27 日的研究報告中將 Tarsus Pharmaceuticals 的股票評級提升至 “買入”，並設定了 72.00 美元的目標價。兩位研究分析師對該股票給予了持有評級，五位給予了買入評級，一位給予了強烈買入評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 66.67 美元。</p>
<p><strong>閲讀我們關於 TARS 的最新報告</strong></p>
<h2>Tarsus Pharmaceuticals 股價表現</h2>
<p>週一，TARS 股價下跌 0.36 美元，達到 42.59 美元。該公司股票交易量為 43,739 股，而其平均交易量為 699,781 股。該股票的市值為 17.9 億美元，市盈率為 -11.21，貝塔值為 0.94。Tarsus Pharmaceuticals 的 12 個月最低價為 20.08 美元，最高價為 57.28 美元。該股票的 50 日移動平均價格為 46.93 美元，200 日移動平均價格為 48.96 美元。該公司的債務與股本比率為 0.30，流動比率為 5.42，速動比率為 5.38。</p>
<p>Tarsus Pharmaceuticals (NASDAQ:TARS - 獲取免費報告) 最近在 5 月 1 日發佈了其財報。該公司報告本季度每股收益為 -0.64 美元，超出市場共識預期的 -0.69 美元 0.05 美元。該公司本季度的收入為 7834 萬美元，而分析師預期為 7250 萬美元。Tarsus Pharmaceuticals 的淨利潤率為 -103.64%，股本回報率為 -55.86%。賣方分析師預計 Tarsus Pharmaceuticals 本年度每股收益將為 -3.17 美元。</p>
<h2>Tarsus Pharmaceuticals 的內部買賣</h2>
<p>在其他消息中，首席執行官 Bobak R. Azamian 於 3 月 18 日在一筆交易中出售了 7,131 股該股票。股票以平均價格 46.29 美元出售，總價值為 330,093.99 美元。出售完成後，首席執行官現在擁有 70,720 股公司股票，價值 3,273,628.80 美元。這代表其持股比例減少了 9.16%。該交易已在證券交易委員會的法律文件中披露，相關信息可在此鏈接查看。此外，首席法律顧問 Bryan Wahl 於 3 月 20 日在一筆交易中出售了 3,084 股該公司的股票。該股票以平均價格 50.11 美元出售，總交易額為 154,539.24 美元。交易完成後，首席法律顧問現在直接擁有 51,712 股公司股票，價值約 2,591,288.32 美元。這代表其持股比例減少了 5.63%。該交易的披露信息可在此處找到。內部人士在上個季度出售了價值 1,581,173 美元的 32,542 股公司股票。公司內部人士持有 8.25% 的公司股票。</p>
<h2>對 Tarsus Pharmaceuticals 的對沖基金看法</h2>
<p>對沖基金最近對該公司的持倉進行了調整。Crowley Wealth Management Inc. 在第四季度收購了 Tarsus Pharmaceuticals 的新股份，價值約 25,000 美元。GF Fund Management CO. LTD. 在第四季度收購了 Tarsus Pharmaceuticals 的新股份，價值 44,000 美元。Amalgamated Bank 在第一季度將其在 Tarsus Pharmaceuticals 的股份增加了 30.1%。Amalgamated Bank 目前擁有 1,274 股公司股票，價值 65,000 美元，此前在上個季度又購買了 295 股。Quarry LP 在第四季度收購了 Tarsus Pharmaceuticals 的新股份，價值約 166,000 美元。最後，AlphaQuest LLC 在第一季度收購了 Tarsus Pharmaceuticals 的新股份，價值約 189,000 美元。機構投資者和對沖基金持有公司 90.01% 的股票。</p>
<h2>關於 Tarsus Pharmaceuticals</h2>
<p>(獲取免費報告)</p>
<p>Tarsus Pharmaceuticals, Inc. 是一家商業階段的生物製藥公司，專注於在美國開發和商業化新型眼科治療候選藥物。該公司的主要產品候選藥物是 XDEMVY，一種用於治療由蠕形蟎感染引起的瞼緣炎的新型治療藥物，以及用於治療瞼板腺疾病。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Tarsus Pharmaceuticals</li>
<li>製造業股票投資</li>
<li>在 Okta 中買入，前景沒有問題</li>
<li>投資者最重要的沃倫·巴菲特股票：他自己的股票</li>
<li>儘管亞馬遜交易存在擔憂，分析師對 Marvell 股票持樂觀態度</li>
<li>納斯達克證券交易所是什麼？</li>
<li>你可能錯過的 3 只高風險高回報的黃金 ETF</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEFSUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEFSUw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Tarsus Pharmaceuticals 嗎？</h2>
<p>在考慮 Tarsus Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Tarsus Pharmaceuticals 並不在名單上。</p>
<p>雖然 Tarsus Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TARS

<p>Oppenheimer 已經開始對 Tarsus Pharmaceuticals (NASDAQ:TARS) 進行覆蓋，給予 “跑贏大盤” 的評級，並設定目標價為 75.00 美元，意味着相較於其前一交易日收盤價有 76.10% 的潛在上漲空間。其他分析師的意見各不相同，巴克萊將其目標價下調至 60.00 美元，而高盛則將其上調至 51.00 美元。該股票目前的共識評級為 “適度買入”，平均目標價為 66.67 美元。Tarsus 在上個季度報告的收入為 7834 萬美元，超出預期，市值為 17.9 億美元</p>

<p>Oppenheimer initiated coverage on shares of Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) in a note issued to investors on Monday. The brokerage set an &#34;outperform&#34; rating and a $75.00 price target on the stock. Oppenheimer's target price indicates a potential upside of 76.10% from the company's previous close.</p>
<div class="lb-trans"><p>Oppenheimer 在週一向投資者發佈的報告中開始覆蓋 Tarsus Pharmaceuticals (NASDAQ:TARS - 獲取免費報告) 的股票。該券商對該股票設定了 “跑贏大盤” 的評級，並給出了 75.00 美元的目標價。Oppenheimer 的目標價表明該公司股價有潛在的 76.10% 上漲空間。</p>
</div><p>Get <strong>Tarsus Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Tarsus Pharmaceuticals</strong> 的提醒：</p>
</div><p>Other equities research analysts also recently issued reports about the stock. Barclays reduced their price target on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an &#34;overweight&#34; rating on the stock in a research note on Wednesday, February 26th. The Goldman Sachs Group upped their target price on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a &#34;neutral&#34; rating in a research note on Monday, May 5th. Wall Street Zen downgraded shares of Tarsus Pharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Thursday, May 22nd. Guggenheim increased their price objective on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, May 2nd. Finally, HC Wainwright raised shares of Tarsus Pharmaceuticals to a &#34;buy&#34; rating and set a $72.00 price objective on the stock in a research report on Tuesday, May 27th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $66.67.</p>
<div class="lb-trans"><p>其他股票研究分析師最近也對該股票發佈了報告。巴克萊將 Tarsus Pharmaceuticals 的股票目標價從 62.00 美元下調至 60.00 美元，並在 2 月 26 日的研究報告中對該股票設定了 “增持” 評級。高盛將 Tarsus Pharmaceuticals 的股票目標價從 46.00 美元上調至 51.00 美元，並在 5 月 5 日的研究報告中給予該股票 “中性” 評級。華爾街 Zen 在 5 月 22 日的研究報告中將 Tarsus Pharmaceuticals 的股票評級從 “買入” 下調至 “持有”。古根海姆在 5 月 2 日的研究報告中將 Tarsus Pharmaceuticals 的股票目標價從 78.00 美元上調至 84.00 美元，並給予該公司 “買入” 評級。最後，HC Wainwright 在 5 月 27 日的研究報告中將 Tarsus Pharmaceuticals 的股票評級提升至 “買入”，並設定了 72.00 美元的目標價。兩位研究分析師對該股票給予了持有評級，五位給予了買入評級，一位給予了強烈買入評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 66.67 美元。</p>
</div><p><strong>Read Our Latest Report on TARS</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 TARS 的最新報告</strong></p>
</div><h2>Tarsus Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Tarsus Pharmaceuticals 股價表現</h2>
</div><p>TARS traded down $0.36 on Monday, reaching $42.59. 43,739 shares of the company's stock were exchanged, compared to its average volume of 699,781. The stock has a market cap of $1.79 billion, a PE ratio of -11.21 and a beta of 0.94. Tarsus Pharmaceuticals has a twelve month low of $20.08 and a twelve month high of $57.28. The stock's fifty day moving average price is $46.93 and its 200-day moving average price is $48.96. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38.</p>
<div class="lb-trans"><p>週一，TARS 股價下跌 0.36 美元，達到 42.59 美元。該公司股票交易量為 43,739 股，而其平均交易量為 699,781 股。該股票的市值為 17.9 億美元，市盈率為 -11.21，貝塔值為 0.94。Tarsus Pharmaceuticals 的 12 個月最低價為 20.08 美元，最高價為 57.28 美元。該股票的 50 日移動平均價格為 46.93 美元，200 日移動平均價格為 48.96 美元。該公司的債務與股本比率為 0.30，流動比率為 5.42，速動比率為 5.38。</p>
</div><p>Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.05. The company had revenue of $78.34 million for the quarter, compared to analyst estimates of $72.50 million. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. Sell-side analysts expect that Tarsus Pharmaceuticals will post -3.17 EPS for the current year.</p>
<div class="lb-trans"><p>Tarsus Pharmaceuticals (NASDAQ:TARS - 獲取免費報告) 最近在 5 月 1 日發佈了其財報。該公司報告本季度每股收益為 -0.64 美元，超出市場共識預期的 -0.69 美元 0.05 美元。該公司本季度的收入為 7834 萬美元，而分析師預期為 7250 萬美元。Tarsus Pharmaceuticals 的淨利潤率為 -103.64%，股本回報率為 -55.86%。賣方分析師預計 Tarsus Pharmaceuticals 本年度每股收益將為 -3.17 美元。</p>
</div><h2>Insider Buying and Selling at Tarsus Pharmaceuticals</h2>
<div class="lb-trans"><h2>Tarsus Pharmaceuticals 的內部買賣</h2>
</div><p>In other news, CEO Bobak R. Azamian sold 7,131 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $330,093.99. Following the completion of the sale, the chief executive officer now owns 70,720 shares of the company's stock, valued at $3,273,628.80. This represents a 9.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, General Counsel Bryan Wahl sold 3,084 shares of the firm's stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $50.11, for a total transaction of $154,539.24. Following the transaction, the general counsel now directly owns 51,712 shares of the company's stock, valued at approximately $2,591,288.32. This represents a 5.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 32,542 shares of company stock valued at $1,581,173 over the last quarter. Corporate insiders own 8.25% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席執行官 Bobak R. Azamian 於 3 月 18 日在一筆交易中出售了 7,131 股該股票。股票以平均價格 46.29 美元出售，總價值為 330,093.99 美元。出售完成後，首席執行官現在擁有 70,720 股公司股票，價值 3,273,628.80 美元。這代表其持股比例減少了 9.16%。該交易已在證券交易委員會的法律文件中披露，相關信息可在此鏈接查看。此外，首席法律顧問 Bryan Wahl 於 3 月 20 日在一筆交易中出售了 3,084 股該公司的股票。該股票以平均價格 50.11 美元出售，總交易額為 154,539.24 美元。交易完成後，首席法律顧問現在直接擁有 51,712 股公司股票，價值約 2,591,288.32 美元。這代表其持股比例減少了 5.63%。該交易的披露信息可在此處找到。內部人士在上個季度出售了價值 1,581,173 美元的 32,542 股公司股票。公司內部人士持有 8.25% 的公司股票。</p>
</div><h2>Hedge Funds Weigh In On Tarsus Pharmaceuticals</h2>
<div class="lb-trans"><h2>對 Tarsus Pharmaceuticals 的對沖基金看法</h2>
</div><p>Hedge funds have recently made changes to their positions in the business. Crowley Wealth Management Inc. acquired a new stake in Tarsus Pharmaceuticals in the fourth quarter valued at approximately $25,000. GF Fund Management CO. LTD. acquired a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter valued at $44,000. Amalgamated Bank boosted its stake in shares of Tarsus Pharmaceuticals by 30.1% in the 1st quarter. Amalgamated Bank now owns 1,274 shares of the company's stock valued at $65,000 after purchasing an additional 295 shares in the last quarter. Quarry LP acquired a new position in Tarsus Pharmaceuticals during the 4th quarter worth about $166,000. Finally, AlphaQuest LLC acquired a new stake in shares of Tarsus Pharmaceuticals in the 1st quarter valued at approximately $189,000. Institutional investors and hedge funds own 90.01% of the company's stock.</p>
<div class="lb-trans"><p>對沖基金最近對該公司的持倉進行了調整。Crowley Wealth Management Inc. 在第四季度收購了 Tarsus Pharmaceuticals 的新股份，價值約 25,000 美元。GF Fund Management CO. LTD. 在第四季度收購了 Tarsus Pharmaceuticals 的新股份，價值 44,000 美元。Amalgamated Bank 在第一季度將其在 Tarsus Pharmaceuticals 的股份增加了 30.1%。Amalgamated Bank 目前擁有 1,274 股公司股票，價值 65,000 美元，此前在上個季度又購買了 295 股。Quarry LP 在第四季度收購了 Tarsus Pharmaceuticals 的新股份，價值約 166,000 美元。最後，AlphaQuest LLC 在第一季度收購了 Tarsus Pharmaceuticals 的新股份，價值約 189,000 美元。機構投資者和對沖基金持有公司 90.01% 的股票。</p>
</div><h2>About Tarsus Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Tarsus Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.</p>
<div class="lb-trans"><p>Tarsus Pharmaceuticals, Inc. 是一家商業階段的生物製藥公司，專注於在美國開發和商業化新型眼科治療候選藥物。該公司的主要產品候選藥物是 XDEMVY，一種用於治療由蠕形蟎感染引起的瞼緣炎的新型治療藥物，以及用於治療瞼板腺疾病。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Tarsus Pharmaceuticals</li>
<li>Manufacturing Stocks Investing</li>
<li>Buy The Dip in Okta, There’s Nothing Wrong With the Outlook</li>
<li>The Most Important Warren Buffett Stock for Investors: His Own</li>
<li>Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern</li>
<li>What is the NASDAQ Stock Exchange?</li>
<li>3 High-Risk, High-Reward Gold ETFs You May Be Missing</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Tarsus Pharmaceuticals</li>
<li>製造業股票投資</li>
<li>在 Okta 中買入，前景沒有問題</li>
<li>投資者最重要的沃倫·巴菲特股票：他自己的股票</li>
<li>儘管亞馬遜交易存在擔憂，分析師對 Marvell 股票持樂觀態度</li>
<li>納斯達克證券交易所是什麼？</li>
<li>你可能錯過的 3 只高風險高回報的黃金 ETF</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEFSUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=TARS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Tarsus Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Tarsus Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Tarsus Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Tarsus Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Tarsus Pharmaceuticals 並不在名單上。</p>
</div><p>While Tarsus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Tarsus Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Tarsus Pharmaceuticals (NASDAQ:TARS) Now Covered by Oppenheimer

Tarsus Pharmaceuticals（NASDAQ:TARS）現已被 Oppenheimer 納入研究覆蓋範圍